NRIX Stock Analysis: Buy, Sell, or Hold?
NRIX - Nurix Therapeutics, Inc. Common stock
$14.76
-0.77 (-4.96%)
▼
5d:
+2.29%
30d:
-8.38%
90d:
-23.58%
BUY
MODERATE Confidence
Analysis Updated: Mar 27, 2026 12:00 AM ET
Earnings: Apr 14, 2026
14d
Get Alerted When NRIX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: NRIX shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: NRIX shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: NRIX is currently trading at $14.76, which is considered fair relative to its 30-day fair value range of $15.01 to $15.96.
Technical Outlook: Technically, NRIX is showing sideways momentum. Immediate support is located at $14.01, while resistance sits at $16.20. Short-term momentum is weak, with the stock down 5.0% recently.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $30.00 (+103.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, NRIX is showing sideways momentum. Immediate support is located at $14.01, while resistance sits at $16.20. Short-term momentum is weak, with the stock down 5.0% recently.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $30.00 (+103.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Fair Price Range
$15.01 -
$15.96
Company Quality Score
54/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
69.5%
All Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-5.0%)
- BULLISH: Trading 103.3% below Wall St target ($30.00)
Fair Price Analysis
30-Day Fair Range
$15.01 -
$15.96
Current vs Fair Value
FAIR
Support & Resistance Levels
Support Level
$14.01
Resistance Level
$16.20
Current Trend
Sideways
Technical data as of
Mar 27, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-4.88
Wall Street Target
$30.00
(+103.3%)
Revenue Growth (YoY)
2.2%
Share & Embed Analysis
Last updated: March 30, 2026 8:26 AM ET
Data refreshes hourly during market hours. Next update: 9:26 AM
Data refreshes hourly during market hours. Next update: 9:26 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is NRIX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
5
Sells
Net
INSIDERS SELLING
Recent Transactions
Gwenn Hansen
SELL
4895 shares
2026-01-30
Houte Hans Van
SELL
3661 shares
2026-01-30
Houte Hans Van
SELL
6284 shares
2025-11-03
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$222 | 62 BUY |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$54 | 54 HOLD |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$93 | 56 HOLD |
|
CRNX
Crinetics Pharmaceutical… |
STRONG BUY
17 analysts |
$84 | 61 BUY |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$108 | 63 BUY |
